Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On July 15, 2020, Edwards Lifesciences Corporation, a Delaware corporation (the "Company"), announced that Paul A. LaViolette was appointed to the Company's Board of Directors, effective July 13, 2020. The Board also appointed Mr. LaViolette to serve as a member of the Compensation and Governance Committee of the Board of Directors.

There is no arrangement or understanding between Mr. LaViolette and any other persons pursuant to which he was selected as a director. Mr. LaViolette has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. LaViolette will receive the same compensation for his services as a director as the Company's other nonemployee directors as described under "Director Compensation" in the Company's 2020 Proxy Statement filed with the Securities and Exchange Commission (the "SEC") on March 25, 2020. The Company will also enter into its standard form of indemnification agreement with Mr. LaViolette, which agreement is filed as Exhibit 10.20 to the Company's Form 10-K for the fiscal year ended December 31, 2011, filed with the SEC on February 27, 2012.

A copy of the press release announcing his appointment is filed as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits


  99.1        Press Release dated July 15, 2020

  104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses